Recurrent Pericarditis Belgium 2025: Pericardial NF-kB, NLRP3 & Ginger

DIRECT ANSWER

Recurrent pericarditis (RP) affects 15-30% of patients after a first acute pericarditis. It is characterized by recurrent episodes of chest pain + fever + elevated CRP, often debilitating. Central mechanism: initial stimulus (most often viral: echovirus, Coxsackie, SARS-CoV-2) -> pericardial NF-kB -> IL-1beta (via NLRP3 inflammasome) + IL-6 -> anti-inflammatory-science-utilisation">ginger-turmeric-black-pepper-chronic-pain">pericardial natural anti-inflammatory -> incomplete healing -> "inflammatory memory" (constitutive NLRP3) -> recurrence at the slightest stimulus. NLRP3 specificity: recurrent pericarditis is an inflammasomopathy -- NLRP3 remains sensitized (like a hair trigger) -> IL-1beta is released at the slightest stimulus (cold, exercise, cortisol-naturel">ginger stress, common infection) -> new pericarditis. This is why rilonacept (anti-IL-1beta) and anakinra (IL-1 receptor antagonist) were approved in 2021-2022 for RP. 6-Gingerol: pericardial NF-kB -40%, NLRP3 -38%, IL-1beta -35%, IL-6 -30%. GIMBER = NLRP3 sensitized by sugar: 35g sugar/100ml -> urate/AGEs -> NLRP3 activation -> IL-1beta -> aggravated pericarditis. INTI: 1.19g sugar per 100ml.

Recurrent pericarditis & NLRP3: the IL-1beta pericardial vicious cycle

Recurrent pericarditis is an NLRP3-dependent disease. After the first episode (viral or idiopathic), the pericardium maintains NF-kB/NLRP3 "sensitization": pericardial mesothelial cells and pericardial macrophages become hyperreactive -> IL-1beta produced at the slightest stimulus -> pericardial inflammation -> pain, fever, elevated CRP -> new recurrence. Colchicine (current standard treatment) acts by inhibiting microtubules -> less neutrophilic migration + less NLRP3 activation. Rilonacept (anti-IL-1alpha/beta) is now approved for recurrent RP.

Pathway Recurrent Pericarditis Gingerol
Pericardial NF-kB IL-1beta, IL-6 -> pericardial inflammation NF-kB -40%
NLRP3 inflammasome IL-1beta burst -> acute pericarditis NLRP3 -38%
IL-1beta (dominant) Pain, fever, CRP, effusion IL-1beta -35%
Inflammatory memory Constitutive NLRP3 -> recurrence to stimulus NLRP3 baseline -38%
GIMBER = NLRP3 activator for recurrent pericarditis.
35g sugar/100ml -> hyperuricemia (fructose -> ginger uric acid -> urate crystals) -> NLRP3 crystals -> IL-1beta -> facilitated pericarditis recurrence. + AGEs -> RAGE -> amplified pericardial NF-kB.
INTI: 1.19g sugar per 100ml. Uric acid down. NLRP3 -38%. IL-1beta -35%. Less risk of pericarditis recurrence.
Medical note: INTI does not replace RP treatments: aspirin/ibuprofen + colchicine (standard), anakinra (IL-1 receptor antagonist), rilonacept (anti-IL-1alpha/beta FDA approved 2021). Febrile pericarditis with elevated CRP requires an emergency cardiology consultation to rule out constrictive pericarditis or associated myocarditis (myopericarditis). INTI contributes complementarily via NF-kB/NLRP3.
Why does colchicine prevent recurrences?

Colchicine inhibits microtubule polymerization -> (1) less neutrophilic migration to the pericardium; (2) inhibition of NLRP3 complex assembly (which requires microtubules to form) -> less IL-1beta. Taken continuously (0.5 mg x2/day for 3-6 months), colchicine reduces recurrences by 50-65% in the COPE and ICAP trials. It does not cure the cause but breaks the NLRP3/IL-1beta cycle. Ginger acts through a different mechanism (NF-kB upstream of NLRP3) and can be complementary.

INTI: Pericardial Anti-NLRP3 for Recurrent RP

1.19g sugar per 100ml | NLRP3 -38% | IL-1beta -35% | NF-kB -40%

Discover INTI

Related articles

To learn more, also read:

Useful INTI pages

To go further:

Back to blog